The news of recent days touted the potential of a new heart drug by Novartis. Today's news is not favorable to Novartis. Its Japanese subsidiary has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukemia and other cancer drugs, reportedly including some fatalities.
This follows news in July when Japanese prosecutors laid charges against the unit over claims that falsified data was used to exaggerate the benefits of a popular blood-pressure drug. Plus, Japan indicted a former employee, alleging he manipulated the data in clinical studies that were later used in marketing the drug Valsartan.
No comments:
Post a Comment